Peptide Synthesis Market Projected to Fix USD 2277.59 Mn by 2034

Peptide Synthesis Market Overview: Size, Trends, and Developments
The global peptide synthesis market was valued at USD 686.59 million in 2024 and is expected to grow to USD 774.06 million in 2025. By 2034, the market is projected to reach approximately USD 2277.59 million, expanding at a compound annual growth rate (CAGR) of 12.74% from 2025 to 2034. This growth is driven by the rising incidence of chronic diseases, increased research and development efforts, and technological advancements.

Download Statistical Data: https://www.towardshealthcare.com/download-statistics/5393

Peptide Synthesis: The Future of Biotechnology

Peptides are short chains of amino acids that form the building blocks of proteins. Peptide synthesis refers to the process of linking amino acids through peptide or amide bonds to create these short chains. This can be done using either solid-phase or solution-phase synthesis methods. Synthetic peptides are utilized in various fields, including protein function studies and as treatments for chronic diseases like cancer.

The growing prevalence of chronic illnesses has spurred research into synthesizing new peptides. These peptides can be used as therapeutics to treat such disorders or as tools to understand the proteins involved in diseases. The expanding biotechnology and cell biology industries further accelerate the market's growth. Moreover, ongoing advancements in technology are driving the development of novel peptide synthesis methods. Increasing investments from both governmental and private organizations also play a significant role in market expansion.

Noteworthy Market Trends

• Amneal Pharmaceuticals, in October 2024, announced an investment of Rs. 1,680 crore (approximately $200 million) over the next few years to develop peptide-based drugs for metabolic diseases and obesity.

• Snapdragon Chemistry, a subsidiary of Cambrex, introduced new liquid-phase peptide synthesis (LPPS) technology in September 2024. This innovation reduces the need for solvents and excess reagents compared to traditional solid-phase synthesis methods.

• Donaldson Company, Inc. and PolyPeptide Group AG joined forces in May 2024 to create an environmentally friendly peptide manufacturing process through a new solvent recovery system.

Impact of AI on Peptide Synthesis

Artificial Intelligence (AI) and Machine Learning (ML) have the potential to revolutionize the peptide synthesis process. These technologies can help design new peptides, validate drug discovery, and enhance the drug development process. AI and ML can assist in identifying diverse peptide activities and assessing protein-peptide interactions, leading to more efficient screening and improved drug development. Additionally, these technologies enable automation in peptide synthesis, increasing productivity and streamlining the process. AI also helps predict the bioactivity and toxicity of peptides, allowing researchers to prioritize potential candidates earlier in the development stage.

Market Dynamics

Drivers:

Growing Research and Development: Increasing research and development efforts are a major driver of the peptide synthesis market. The rising prevalence of chronic diseases has spurred research into synthetic peptides, particularly for conditions like cancer, infectious diseases, immunology, and metabolic disorders. The growing demand for peptide-based therapies, including vaccines, biomarkers, and mass spectrometry reagents, is driving the market forward.

Sustainability Issues and High Purification Costs: Sustainability challenges in the peptide synthesis process, such as the use of hazardous solvents and the difficulty of recycling materials, can hamper market growth. Additionally, the high costs associated with peptide purification, especially for longer peptides, present another challenge for the industry.

Opportunities:

Recombinant Peptide Synthesis: Recombinant peptide synthesis techniques are seen as a promising future for the market. These techniques, which involve the expression of peptides in bacterial, yeast, or mammalian cells, can produce peptides more efficiently and at larger scales. Recombinant methods also enhance the purity and stability of peptides, making them a reliable option for large-scale peptide production.

Segment Insights

• Reagents & Consumables Segment Leads the Market
In 2023, the reagents & consumables segment dominated the peptide synthesis market. These products, such as building blocks, chelators, coupling reagents, protecting reagents, amino acids, and resins, are essential for peptide synthesis. They help accelerate the synthesis process and enhance the specificity of the peptides produced. This results in a wide variety of customizable and flexible peptide products.

• Equipment Segment: The Fastest Growing
The equipment segment is expected to experience the highest growth rate during the forecast period. Equipment used in peptide synthesis ensures precise and controlled addition of amino acids. It plays a key role in drug lead optimization, structure-activity studies, and receptor binding studies. Innovations in technology continue to drive the growth of this segment, with new equipment being developed to increase efficiency and speed.

• Liquid Phase Peptide Synthesis Segment Leads
In 2023, the liquid phase peptide synthesis (LPPS) method led the market. LPPS, which synthesizes peptides in solution, has gained popularity because it helps scale peptide production while reducing the use of reagents and solvents. This makes it more environmentally friendly than other methods. LPPS also simplifies the detection of side reactions, as products are purified after each step.

• Hybrid Technology Segment: The Fastest Growing
The hybrid technology segment is forecasted to grow at the highest rate during the study period. This approach combines two different methods to synthesize peptides, offering the benefits of both chemical synthesis and recombinant methods. Hybrid technology enables the production of high-quality peptides on a large scale, offering researchers flexibility and precision. This method is seen as the future of peptide synthesis, particularly for producing complex structures and modifications that are difficult to achieve using a single technique.

• Therapeutics Segment Holds the Largest Share
In 2023, the therapeutics segment held the largest share of the peptide synthesis market. Peptide-based drugs are used to treat a wide range of chronic diseases by acting as inhibitors or activators. The growing prevalence of chronic disorders has led to increased demand for peptide therapeutics, driving growth in this segment. Additionally, the approval of numerous peptide-based drugs by regulatory authorities, such as the US FDA, further fuels this expansion. Peptides offer advantages over traditional small molecules, including better target specificity, potency, and fewer side effects.

•Diagnosis Segment: The Fastest Growing
The diagnosis segment is expected to grow rapidly in the coming years. Peptides play a crucial role in diagnosing various diseases by detecting and quantifying biomarkers in biological samples. They are also used in imaging techniques due to their good tissue penetration and non-immunogenicity. Government policies promoting early detection and accurate diagnosis of chronic diseases are contributing to the growth of this segment.

• Pharmaceutical & Biotechnology Companies Segment Leads
In 2023, pharmaceutical and biotechnology companies dominated the peptide synthesis market. These companies benefit from strong infrastructure, access to capital, and the availability of skilled professionals. They also have specialized labs equipped with advanced tools for peptide synthesis, enhancing their ability to innovate and develop new peptide-based therapies.

• Contract Development & Manufacturing Organizations (CDMO) and Contract Research Organizations (CRO): The Fastest Growing
The CDMO/CRO segment is expected to grow the fastest during the forecast period. This growth is driven by the increasing number of CDMOs and CROs, which provide essential infrastructure and skilled personnel for peptide synthesis. By outsourcing peptide synthesis, pharmaceutical and biotechnology companies can reduce time and costs while ensuring high-quality results.

Regional Insights

North America Leads with Key Player Presence

In 2023, North America captured the largest share of the peptide synthesis market. The region benefits from a growing number of chronic disorders, cutting-edge research facilities, and the presence of major industry players. Companies like Thermo Fisher Scientific, Sigma Aldrich, GenScript, and Aragen Life Sciences are significantly contributing to market expansion. Furthermore, the surge in new product launches continues to fuel this growth. In 2023, the U.S. FDA approved five new peptides aimed at diagnosing and treating various chronic and rare conditions. Additionally, substantial funding from both the U.S. and Canadian governments is supporting the development of peptide-based treatments in the region.

Asia-Pacific's Growth Driven by Government Support

Asia-Pacific is set to experience the fastest growth in the peptide synthesis market in the coming years. The rapid adoption of advanced technologies, along with increased investments and collaborations, is driving the market forward. The region's pharmaceutical and biotech industries are expanding rapidly. India, with its robust generic pharmaceutical sector, ranks as the world's third-largest by volume. The Indian government's funding initiatives are strengthening the production of cost-effective generics and spurring the development of innovative drugs. Similarly, China's government is encouraging pharmaceutical R&D through international collaborations, with around 220 innovative drug licensing and partnership deals worth $37 billion made in 2023 alone.

Leading Companies in the Peptide Synthesis Market

• Aapptec Peptides
• AnaSpec
• Aragen Life Sciences
• Aurigene Pharmaceutical Services
• Bachem Holding
• Biomatik
• Bio-Synthesis, Inc.
• CPC Scientific
• GenScript Biotech
• LifeTein LLC
• ProteoGenix
• Sigma Aldrich
• Thermo Fisher Scientific
• USV India

Industry Insights from Market Leaders

Dr. Brad Pentelute, CEO of Amide Technologies, noted that the growing prevalence of cancers and metabolic disorders, along with increasing investments in drug research and development, is driving the demand for peptide-based therapeutics. He highlighted that the company's advanced synthetic capabilities enable rapid development of complex peptides, helping biopharma companies meet the increasing global demand.

Recent Market Developments

• In July 2024, researchers at the University of Manchester introduced a more efficient and sustainable method using ligase enzymes to synthesize peptide-based medicines for cancer treatment.

• In January 2024, Vapourtec launched the Peptide-Pilot, a solid-phase peptide synthesizer designed to drastically reduce the drug development cycle from weeks to hours.

Source: https://www.towardshealthcare.com/insights/peptide-synthesis-market-sizing

Baner

Buy Premium Global Insight:https://www.towardshealthcare.com/price/5393

Review the Full TOC for the Peptide Synthesis Market Report:https://www.towardshealthcare.com/table-of-content/peptide-synthesis-market-sizing

Get the latest insights on industry segmentation with our Annual Membership: https://www.towardshealthcare.com/get-an-annual-membership

About Us

Towards Healthcare is a leading global provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations. We are a global strategy consulting firm that assists business leaders in gaining a competitive edge and accelerating growth. We are a provider of technological solutions, clinical research services, and advanced analytics to the healthcare sector, committed to forming creative connections that result in actionable insights and creative innovations.

We've prepared a service to support you. Please feel free to contact us at sales@towardshealthcare.com

Web: https://www.towardshealthcare.com

For Latest Update Follow Us: https://www.linkedin.com/company/towards-healthcare

This release was published on openPR.